Construction of Synthetic Biology Innovation Platform: Ruifudi and Tianmu Biology Establish Strategic Cooperation

On December 12, 2024, Revvity and Tianmu Biotechnology announced a strategic partnership to jointly explore the synthetic biology market. This cooperation aims to promote innovation, accelerate the research and application of synthetic biology technology in China, and inject new impetus and vitality into the industry's development.

Mr. Liu Jiang, Vice President of Ruifudi and General Manager of Greater China (right); Mr. Wang Liyan, Chairman and General Manager of Tianmu Biotechnology (left)

Leading innovation in synthetic biology

Synthetic biology, as a green, efficient, and sustainable production method, has rapidly emerged globally in recent years. In this collaboration, Ruifudi and Tianmu Biology will work together to explore various application scenarios of synthetic biology, integrate their resources and technological advantages, and focus on developing highly integrated, miniaturized, high-efficiency, low-cost, and low-energy innovative solutions. Promote the in-depth application of this cutting-edge technology in the Chinese market, injecting new impetus into the future development of the synthetic biology industry. Focusing on technological breakthroughs and empowering industry development

This strategic cooperation aims to focus on key industry needs and play an important role in the research and application promotion of synthetic biology. Both parties will jointly explore various innovative technological paths to improve industry efficiency, reduce production costs, and expand the application scope of synthetic biology technology in multiple fields, helping the sustainable development of the industry.

Looking ahead to the future, Ruifudi and Tianmu Biotechnology look forward to promoting further development and progress in the field of synthetic biology through this cooperation, creating more possibilities for the industry, and leading new innovative breakthroughs.

Regarding Revvity:

At Revvity, we see 'impossible' as inspiration and 'impossible' as the driving force. Ruifudi provides health science solutions, cutting-edge technology, and professional services, covering the end-to-end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of deep cultivation in fields such as multi omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Ruifudi is breaking through the boundaries of human potential with the power of technology. In 2023, Ruifudi's revenue exceeded 2.7 billion US dollars, with over 11000 employees worldwide, providing diversified services to clients such as pharmaceutical and biotechnology companies, diagnostic laboratories, research institutions, and government agencies. The company is a member of the S&P 500 index and has clients in over 190 countries and regions worldwide.

Regarding Tianmu Biology:

Tianmu Biotechnology is a well-known life science instrument company in China that focuses on technology research and instrument innovation. It has independently built core technology systems such as plasma biotechnology, microfluidics technology, and detection robots, and has developed more than 20 products including plasma mutagenesis breeding equipment, high-throughput single-cell droplet sorting equipment, droplet continuous propagation and evolution equipment, and online detection equipment for biological culture processes. After years of research and development, the company's products have achieved full coverage across multiple levels of cell culture, detection, and sorting systems, from skin, nano, and micro upgrades to milliliters and upgrades. The company has also creatively connected different systems, maximizing the advantages of each level of system; The combination of relevant instruments and equipment is flexible and widely applicable, helping to achieve a significant increase in research and development efficiency. The company has strong research and development capabilities, always guided by customer needs, and adheres to the combination of equipment innovation, method development, and technical services. Currently, the Tianmu team has completed the development of dozens of microsystem detection methods. Innovation driven, customer first. Tianmu Biotechnology will continuously provide efficient research and development platforms and one-stop solutions for fields such as biological fermentation, synthetic biology, enzyme engineering, and biomedicine through technological and equipment innovation, contributing to the development of the biotechnology industry.